{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Patients who could not be assessed quantitatively for disease response for any reason.","groups":[{"description":"Assigned to 60 mg dose, 6 doses/cycle","id":"OG000","title":"Selinexor (PTCL)"},{"description":"Assigned to 60 mg dose, 6 doses/cycle (6 patients); Assigned to 60 mg dose, 8 doses/cycle (1 patient)","id":"OG001","title":"Selinexor (CTCL)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent to Treat population","reportingStatus":"POSTED","timeFrame":"Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.","title":"Best Overall Response: Not Evaluable (NE)","type":"PRIMARY","unitOfMeasure":"Participants"}